Cargando…

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?

Detalles Bibliográficos
Autores principales:	Glas, Martin, Kebir, Sied
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918487/ https://www.ncbi.nlm.nih.gov/pubmed/31897090 http://dx.doi.org/10.1177/1758835919887667

Ejemplares similares

Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes
por: Gaudino, Simona, et al.
Publicado: (2022)

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
por: Schäfer, Niklas, et al.
Publicado: (2019)

Multifocal cerebellar liponeurocytoma: How to deal with it?
por: Ghedira, Khalil, et al.
Publicado: (2023)

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005–2022
por: Oster, Christoph, et al.
Publicado: (2023)

Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma
por: Chiesa, Silvia, et al.
Publicado: (2022)

Clinical activity of regorafenib in elderly patients with recurrent glioblastoma
por: Fasano, Morena, et al.
Publicado: (2023)

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients
por: Hattingen, Elke, et al.
Publicado: (2017)

Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Hou, Jing-Yu, et al.
Publicado: (2022)

Tinnitus revival during COVID-19 lockdown: how to deal with it?
por: Anzivino, Roberta, et al.
Publicado: (2020)

How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis
por: Jabbarli, Ramazan, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Quantitative T1‐mapping detects cloudy‐enhancing tumor compartments predicting outcome of patients with glioblastoma
por: Müller, Andreas, et al.
Publicado: (2016)

Right Ventricular Dysfunction in COVID-19 ECMO—A Red Herring or the Real Deal?
por: Kopanczyk, Rafal, et al.
Publicado: (2022)

A Call for Standardization in Interventional Radiology Practice: How to Deal with Spontaneous Retroperitoneal Haemorrhage?
por: Calabrese, Francesca, et al.
Publicado: (2023)

Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma
por: Schmidt, Teresa, et al.
Publicado: (2023)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

How Do Children Deal With Conflict? A Developmental Study of Sequential Conflict Modulation
por: Smulders, Silvan F. A., et al.
Publicado: (2018)

A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma
por: Kebir, Sied, et al.
Publicado: (2020)

HBR guide to dealing with conflict
por: Gallo, Amy
Publicado: (2017)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

Dealing of mass casualty in ophthalmology - A challenge
por: Pandey, Kalpana, et al.
Publicado: (2010)

Can telerehabilitation deal with cognitive disturbances in epilepsy?
por: Giovagnoli, Anna Rita
Publicado: (2020)

How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience
por: Kawanami, Gustavo Hideki, et al.
Publicado: (2021)

China 88: The Real China and How to Deal with It
por: Delios, Andrew
Publicado: (2014)

Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI
por: Galldiks, Norbert, et al.
Publicado: (2019)

Is neutrophil-to-lymphocyte ratio and C-reactive protein the prognostic role in metastatic colorectal cancer using regorafenib?
por: Chen, Xinyang, et al.
Publicado: (2023)

“Thanatophobia”: Physician's Perspective of Dealing with Patients with Fear of Death
por: Balasubramanian, Chandramouli, et al.
Publicado: (2018)

A framework to deal with uncertainty in the age of COVID-19
por: Ng, Qin Xiang, et al.
Publicado: (2020)

Dealing with perceptions related to thrombosis and COVID-19 vaccines
por: Ramírez, Céleo, et al.
Publicado: (2021)

Letter to the editor dealing with paper by Dr Pappone and coworkers
por: Belhassen, Bernard
Publicado: (2023)

Saving the deal: how to avoid financing fiascoes and other real estate deal killers
por: Rumsey, Tracey
Publicado: (2008)

Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression
por: Lu, I-Na, et al.
Publicado: (2021)

Underpowered trials in critical care medicine: how to deal with them?
por: Roozenbeek, Bob, et al.
Publicado: (2010)

Distinct MRI pattern of “pseudoresponse” in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review
por: Gatto, Lidia, et al.
Publicado: (2021)

Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease
por: Mauhin, Wladimir, et al.
Publicado: (2019)

Psychological trauma among the healthcare professionals dealing with COVID-19
por: Brahmi, Neha, et al.
Publicado: (2020)

Dealing with skin reactions to gloves during the COVID-19 pandemic
por: Tabary, Mohammadreza, et al.
Publicado: (2020)

Letter to editor: Covid-19 and dealing with it-lessons learned in Iran
por: Maziar, Pooneh, et al.
Publicado: (2020)

Dealing with two ‘SARS’ outbreaks in Nigeria: The public health implications
por: Okereke, Melody, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_paao7ltuvvhq3r9ff6e28nfdts